Zentalis Pharmaceuticals, Inc.
ZNTL · Pharmaceutical Preparations · 71.2M shares · +85%/yr ↑ shares · EDGAR filings ↗
Reference price $2.42 · est. market cap ~$172M — last insider sale, 2026-02-10 (estimated from the dated SEC Form 4 price × shares outstanding — not a live quote)
Grade
D46Clinical/early-stage biotech — oncology clinical, heavy burn ($125M), funded.
Strengths
- Liquidity — current ratio 6.9 (69th)
Risks
- Pre-revenue, deep losses — per metrics
- Pre-revenue/clinical-stage — history of losses & need for capital per risk factors
- Binary clinical & funding risk — per 10-K
Notable findings
- Exec changeRecent 8-K item 5.02 8-K ↗
- Cash burnNegative free cash flow (-125.2M)
- Fund exitedNotable fund(s) exited this quarter: VANGUARD GROUP INC
- Chronic dilutionShare count +85%/yr over 4y (dilution)
- Insider buyingInsider buying — 1 open-market buy(s) by 1 insider(s) (~$8M, last 6mo) Form 4 ↗
- Trial resultTrial topline data reported — see 8-K for outcome 8-K ↗
- Insider sellingInsider selling — 9 open-market sale(s) by 3 insider(s) (cluster of 3 insiders, last 6mo) Form 4 ↗
- Trial readout soonUpcoming trial readout ~2026-12-01 — PHASE2 · High-Grade Serous Ovarian, Fallopian Tube or Primary Peritoneal Cancer
- Revenue declineRevenue -100.0% YoY
- Notable holderHeld by 5 notable fund(s): RENAISSANCE TECHNOLOGIES LLC, CITADEL ADVISORS LLC, GOLDMAN SACHS GROUP INC +2 more (as of 2026-03-31)
Quarterly revenue
Last 4 quarters · from SEC filings.
Key metrics
Return on equity
-63.4%
Return on assets
-47.4%
Revenue growth (QoQ)
-100.0%
Current ratio
6.9×
Free cash flow
-$125M
EBITDA
-$152M
Tangible book value
$216M
Cash & investments
$246M
Cash runway
8q
Insider transactions · last 18 months
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| 2026-06-16 | Skvarka Jan | Grant | 57K | — |
| 2026-06-16 | Kariuki Enoch | Grant | 57K | — |
| 2026-06-16 | Johnson David Michael | Grant | 57K | — |
| 2026-06-16 | Walker Luke Nathaniel | Grant | 57K | — |
| 2026-06-16 | Myers Scott Dunseth | Grant | 57K | — |
| 2026-05-26 | Campbell Shannon | Grant | 114K | — |
| 2026-02-10 | Vultaggio Vincent | Sell | 6.9K | $2.42 |
| 2026-02-09 | Vultaggio Vincent | Sell | 3.4K | $2.39 |
| 2026-02-09 | Bruns Ingmar | Sell | 335 | $2.39 |
| 2026-02-09 | EASTLAND JULIA MARIE | Sell | 889 | $2.39 |
| 2026-02-06 | EASTLAND JULIA MARIE | Sell | 7.9K | $2.43 |
| 2026-02-06 | Bruns Ingmar | Sell | 3.0K | $2.43 |
| 2026-02-06 | Vultaggio Vincent | Sell | 30K | $2.43 |
| 2026-02-03 | Vultaggio Vincent | Sell | 556 | $2.52 |
| 2026-02-02 | Vultaggio Vincent | Sell | 2.5K | $2.55 |
| 2025-12-31 | WALTERS GROUP | Buy | 6.5M | $1.20 |
| 2025-12-15 | Matrix Capital Management Company, LP | Sell | 7.5M | $1.33 |
| 2025-06-17 | Skvarka Jan | Grant | 58K | — |
| 2025-06-17 | Walker Luke Nathaniel | Grant | 58K | — |
| 2025-06-17 | Johnson David Michael | Grant | 58K | — |
| 2025-06-17 | Kariuki Enoch | Grant | 58K | — |
| 2025-06-17 | Myers Scott Dunseth | Grant | 58K | — |
| 2025-04-30 | Myers Scott Dunseth | Buy | 21K | $1.40 |
| 2025-02-06 | Bruns Ingmar | Buy | 20K | $2.28 |
| 2025-02-03 | Vultaggio Vincent | Grant | 159K | — |
| 2025-02-03 | Vultaggio Vincent | Sell | 2.6K | $1.71 |
| 2025-02-03 | Lackner Mark | Grant | 336K | — |
| 2025-02-03 | Lackner Mark | Sell | 14K | $1.71 |
| 2025-02-03 | Paul Andrea | Grant | 934K | — |
| 2025-02-03 | Paul Andrea | Sell | 13K | $1.71 |
| 2025-02-03 | Bruns Ingmar | Grant | 17K | — |
| 2025-02-03 | EASTLAND JULIA MARIE | Grant | 59K | — |
| 2025-01-31 | Skvarka Jan | Buy | 60K | $1.72 |
| 2025-01-31 | Walker Luke Nathaniel | Buy | 14K | $1.76 |
| 2025-01-31 | EASTLAND JULIA MARIE | Buy | 28K | $1.73 |
| 2025-01-02 | Lackner Mark | Sell | 4.4K | $3.12 |
All non-derivative Form 4 activity (SEC), newest first.
Clinical trials
| Trial | Title | Phase | Status | Primary completion |
|---|---|---|---|---|
| NCT04516447 ↗ | A Study of Azenosertib (ZN-c3) in Patients With Ovarian Cancer Solid Tumor, Epithelial Ovarian Cancer | PHASE1 | Recruiting | 2028-06-30 |
| NCT07546500 ↗ | A Study of Azenosertib (ZN-c3) Versus Investigator's Choice Chemotherapy in Subjects With Platinum-Resistant High-Grade Serous Ovarian, Primary Peritoneal, or Fallopian Tube Cancers Positive for Cyclin E1 Protein Expression Ovarian Cancer | PHASE3 | Recruiting | 2028-05-31 |
| NCT05128825 ↗ | A Study of Azenosertib (ZN-c3) in Subjects With Platinum-Resistant High-Grade Serous Ovarian, Fallopian Tube or Primary Peritoneal Cancer High-Grade Serous Ovarian, Fallopian Tube or Primary Peritoneal Cancer | PHASE2 | Recruiting | 2026-12-01 |
| NCT04814108 ↗ | A Study of Azenosertib (ZN-c3) in Women With Recurrent or Persistent Uterine Serous Carcinoma Uterine Serous Carcinoma | PHASE2 | Completed | 2025-10-22 |
| NCT05198804 ↗ | A Study of Azenosertib (ZN-c3) and Niraparib in Subjects With Platinum-Resistant Ovarian Cancer Ovarian Cancer, Platinum-resistant Ovarian Cancer | PHASE1/PHASE2 | Completed | 2025-10-15 |
| NCT04158336 ↗ | A Study of Azenosertib (ZN-c3) in Participants With Solid Tumors Solid Tumor | PHASE1 | Completed | 2025-05-06 |
| NCT05743036 ↗ | ZN-c3 in Adult Participants With Metastatic Colorectal Cancer Metastatic Colorectal Cancer | PHASE1 | Terminated | 2024-07-16 |
| NCT05682170 ↗ | Study of the ZN-d5 and ZN-c3 in Subjects With Acute Myeloid Leukemia (AML) Acute Myeloid Leukemia (AML) | PHASE1/PHASE2 | Terminated | 2024-07-02 |
| NCT05199337 ↗ | Phase 1/2 Study of ZN-d5 for the Treatment of Relapsed or Refractory Light Chain (AL) Amyloidosis Amyloidosis, AL Amyloidosis | PHASE1/PHASE2 | Completed | 2024-02-14 |
| NCT04500587 ↗ | Phase 1 First in Human Study of ZN-d5 as a Single Agent Acute Myeloid Leukemia, Non Hodgkin Lymphoma | PHASE1 | Completed | 2023-12-12 |
| NCT04833582 ↗ | A Study of Azenosertib (ZN-c3) in Combination With Gemcitabine in Subjects With Osteosarcoma Osteosarcoma | PHASE1 | Completed | 2023-08-30 |
| NCT04854174 ↗ | A Food Effect Study of ZN-d5 in Healthy Female Volunteers Healthy Volunteers | PHASE1 | Completed | 2021-06-30 |
Source: ClinicalTrials.gov (U.S. NIH) · active studies first.
Notable events (8-K)
Recent filings
| Form | Filed | Period | Accession |
|---|---|---|---|
| 8-K | 2026-06-18 | 2026-06-16 | 0001725160-26-000052 ↗ |
| 8-K | 2026-05-27 | 2026-05-22 | 0001725160-26-000049 ↗ |
| 8-K | 2026-05-21 | 2026-05-21 | 0001725160-26-000045 ↗ |
| 10-Q | 2026-05-12 | 2026-03-31 | 0001725160-26-000042 ↗ |
| 8-K | 2026-05-12 | 2026-05-12 | 0001725160-26-000041 ↗ |
| 8-K | 2026-05-05 | 2026-05-05 | 0001725160-26-000033 ↗ |
| 8-K | 2026-04-17 | 2026-04-17 | 0001725160-26-000020 ↗ |
| 8-K | 2026-04-09 | 2026-04-09 | 0001725160-26-000017 ↗ |
| 8-K | 2026-03-26 | 2026-03-26 | 0001725160-26-000010 ↗ |
| 10-K | 2026-03-26 | 2025-12-31 | 0001725160-26-000014 ↗ |
| 8-K | 2026-01-09 | 2026-01-06 | 0001725160-26-000003 ↗ |
| 8-K | 2025-12-15 | 2025-12-15 | 0001725160-25-000164 ↗ |